Via Nova Therapeutics Announces $20 Million Series A Financing from Aditum Bio to Advance Four Antiviral Programs

OAKLAND, Calif., Sept. 7, 2021 -- (Healthcare Sales & Marketing Network) -- Via Nova Therapeutics announced today that it has closed its Series A financing and raised $20 million from Aditum Bio to advance the development of four preclinical antiviral pro... Biopharmaceuticals, Venture Capital Via Nova Therapeutics, influenza, adenovirus, rhinovirus
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news